Catalyst Pharmaceuticals has reported positive top-line results from the MuSK-MG clinical trial of Firdapse to treat patients with myasthenia gravis (MG).

Firdapse is formulated with the firm's amifampridine phosphate designed to treat Lambert-Eaton myasthenic and congenital myasthenic syndromes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The results showed that the trial has met both the co-primary efficacy endpoints of change from baseline (CFB) in total quantitative myasthenia gravis (QMG) score and CFB in total myasthenia gravis activities of daily living (MG-ADL) score.

The randomised, double blind, placebo-controlled, single site, outpatient, investigator-sponsored MuSK-MG proof-of-concept trial evaluated the safety, tolerability and efficacy of amifampridine phosphate in patients with a positive serological test for the anti-MuSK antibodies (MuSK-MG).

"Based on these results, we intend to discuss with FDA conducting a registration trial in the US, evaluating amifampridine phosphate for the symptomatic treatment of patients with MuSK-MG."

Catalyst chief medical officer Gary Ingenito said: "If the significant clinical effect observed in this trial is reproduced in a multicentre trial, amifampridine phosphate would, upon approval, likely become the first line standard of care for MuSK-MG.

See Also:

"Based on these results, we intend to discuss with FDA conducting a registration trial in the US, evaluating amifampridine phosphate for the symptomatic treatment of patients with MuSK-MG."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial involved a cross-over design with three treatment periods to determine the effect of the treatment, as well as correct any subjective carryover from earlier treatment periods into later treatment periods.

The trial's secondary efficacy measures also achieved statistical significance and the drug was found to be well-tolerated.

Firdapse had previously secured orphan medicinal product designation from the European Union (EU) for the treatment of  Lambert-Eaton myasthenic syndrome.